Author(s)

Masataka Ikeda, Mitsugu Sekimoto, Ichiro Takemasa, Tsunekazu Mizushima, Hirofumi Yamamoto, Hideshi Ishii, Yuichiro Doki, Masaki Mori

Department of Surgery, Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Department of Surgery, Natinal Hospital Organization Osaka National Hospital, Osaka, Japan.

Background: We evaluated the feasibility and efficacy of irinotecan (CPT-11) plus tegafur/uracil (UFT) combination chemotherapy in patients with advanced colorectal cancer. Patients and Methods: PK parameters were concurrently measured to confirm the presence of drug interactions in this treatment schedule. CPT-11 was administered intravenously at the dose of 150 mg/m² on days 1, 15. UFT was administered at the dose of 375 mg/m²/day (B.I.D.) on days 3 - 7, 10 - 14, 17 - 21, 24 - 28 repeated every 5 weeks. Results: 31 patients were enrolled. PK parameters for CPT-11, FT, 5-FU and uracil are available from 5 patients. The overall response rate was 16.1%. The median time to treatment discontinuation was 3.9 months. There was no significant difference in PK parameters of CPT-11 between day 1 and day 15 and of UFT between day 3 and day 10. Conclusion: CPT-11 plus UFT combination chemotherapy exhibited a tolerable toxicity profile with acceptable efficacy. Pharmacokinetic analysis showed that there were no drug interactions in this treatment schedule.

Colorectal Neoplasms; Pharmacokinetics; Drug Therapy; Fluorouracil; Tegafur/Uracil; UFT

M. Ikeda, M. Sekimoto, I. Takemasa, T. Mizushima, H. Yamamoto, H. Ishii, Y. Doki and M. Mori, "Feasibility and Efficacy Study of Biweekly Irinotecan Combined with Oral Tegafur/Uracil in Advanced Colorectal Cancer," Journal of Cancer Therapy, Vol. 4 No. 6B, 2013, pp. 8-14. doi: 10.4236/jct.2013.46A2002.